

**Appendix Table F43. Adverse effects that result in discontinuation of the treatment after duloxetine vs. placebo, random effects models**

Reference	Active events/ randomized	Control events/ randomized	Relative risk	Lower (95% CI)	Upper (95% CI)	Weight	Absolute risk difference	Lower (95% CI)	Upper (95% CI)	Weight
<b>Anxiety</b>										
	6/958	0/955	9.158	0.496	169.125	49.29	0.018	-0.001	0.037	16.45
	4/227	0/231	12.959	0.731	229.72	50.71	0.006	0.001	0.012	83.55
Pooled estimate			10.921	1.41	84.603	100	0.008	0	0.016	100
I squared			0.00%				21.20%			
p value for heterogeneity			0.868				0.26			
<b>Asthenia</b>										
	1/60	0/61	2.8	0.115	67.922	23.69	0.01	-0.017	0.036	12.41
	2/136	0/120	4.416	0.214	91.081	26.3	0.015	-0.01	0.04	14
	2/300	0/288	3.049	0.127	73.398	23.81	0.017	-0.028	0.061	4.42
	1/104	0/97	4.801	0.231	99.566	26.2	0.007	-0.005	0.018	69.18
Pooled estimate			3.71	0.786	17.516	100	0.009	-0.001	0.018	100
I squared			0.00%				0.00%			
p value for heterogeneity			0.994				0.926			
<b>Constipation</b>										
Hurley, 2006 <sup>312</sup>	1/955	1/955	0.311	0.013	7.547	37.16	-0.01	-0.038	0.017	2.14
<b>Constipation-discontinuation due to adverse event</b>										
Ghoniem, 2005 <sup>293</sup>	1/97	1/97	2.991	0.312	28.699	62.84	0.002	-0.002	0.006	97.86
Pooled estimate			1.29	0.151	11.001	100	0.002	-0.002	0.006	100
I squared			22.30%				0.00%			
p value for heterogeneity			0.257				0.385			
<b>Dizziness</b>										
Ghoniem, 2005 <sup>293</sup>	2/104	0/97	4.667	0.227	95.996	6.33	0.019	-0.013	0.052	3.74
Millard, 2004 <sup>350</sup>	5/227	0/231	11.193	0.623	201.255	6.93	0.022	0.001	0.043	9.08
Hurley, 2006 <sup>312</sup>	20/958	2/955	9.969	2.337	42.531	27.48	0.019	0.009	0.028	43.41
van Kerrebroeck, 2004 <sup>393</sup>	9/247	1/247	9	1.149	70.504	13.65	0.032	0.008	0.057	6.45
Norton, 2002 <sup>355</sup>	1/140	0/138	2.957	0.122	71.977	5.68	0.007	-0.012	0.027	10.17
Castro-Diaz, 2007 <sup>254</sup>	2/136	0/120	4.416	0.214	91.081	6.32	0.015	-0.01	0.04	6.2
Lin, 2008 <sup>339</sup>	4/60	2/61	2.033	0.387	10.689	21	0.034	-0.043	0.111	0.66
Dmochowski, 2003 <sup>279</sup>	5/344	1/339	4.927	0.579	41.954	12.61	0.012	-0.002	0.025	20.3
Pooled estimate			5.487	2.564	11.739	100	0.017	0.011	0.023	100
I squared			0.00%				0.00%			
p value for heterogeneity			0.914				0.821			

**Appendix Table F43. Adverse effects that result in discontinuation of the treatment after duloxetine vs. placebo, random effects models (continued)**

Reference	Active events/ randomized	Control events/ randomized	Relative risk	Lower (95% CI)	Upper (95% CI)	Weight	Absolute risk difference	Lower (95% CI)	Upper (95% CI)	Weight
<b>Fatigue</b>										
Hurley, 2006 <sup>312</sup>	13/958	2/955	6.48	1.466	28.636	37.22	0.011	0.004	0.019	41.12
Castro-Diaz, 2007 <sup>254</sup>	0/136	2/120	0.177	0.009	3.643	17.1	-0.017	-0.044	0.011	11.54
Bent, 2008 <sup>234</sup>	4/300	0/288	8.869	1.13	69.624	27.67	0.023	0.005	0.041	20.97
Dmochowski, 2003 <sup>279</sup>	9/344	1/339	8.641	0.467	159.784	18.01	0.013	-0.001	0.028	26.37
Pooled estimate			4.021	0.913	17.71	100	0.011	0.001	0.022	100
I squared			42.60%				48.30%			
p value for heterogeneity			0.156				0.121			
<b>Insomnia</b>										
Hurley, 2006 <sup>312</sup>	16/958	2/955	10.267	0.575	183.248	8.47	0.048	0.003	0.093	1.91
van Kerrebroeck, 2004 <sup>393</sup>	5/247	1/247	7.123	0.37	137.119	8.05	0.013	-0.004	0.03	13.25
Castro-Diaz, 2007 <sup>254</sup>	2/136	1/120	7.975	1.839	34.589	32.69	0.015	0.006	0.023	51.81
Lin, 2008 <sup>339</sup>	1/60	0/61	5	0.588	42.488	15.37	0.016	-0.003	0.035	10.37
Dmochowski, 2003 <sup>279</sup>	7/344	1/339	1.765	0.162	19.218	12.34	0.006	-0.02	0.032	5.71
Ghoniem, 2005 <sup>293</sup>	5/104	0/97	3.049	0.127	73.398	6.96	0.017	-0.028	0.061	1.92
Millard, 2004 <sup>350</sup>	3/227	0/231	6.898	0.853	55.767	16.11	0.017	0.001	0.033	15.03
Pooled estimate			5.7	2.463	13.189	100	0.015	0.009	0.021	100
I squared			0.00%				0.00%			
p value for heterogeneity			0.959				0.85			
<b>Nausea</b>										
Ghoniem, 2005 <sup>293</sup>	7/104	0/97	14	0.81	241.894	5.74	0.067	0.016	0.119	3.31
Millard, 2004 <sup>350</sup>	7/227	0/231	15.263	0.877	265.685	5.71	0.031	0.007	0.055	12.96
Hurley, 2006 <sup>312</sup>	48/958	3/955	15.95	4.985	51.03	34.44	0.047	0.033	0.061	27.18
van Kerrebroeck, 2004	13/247	2/247	6.5	1.482	28.503	21.32	0.045	0.015	0.075	8.83
Norton, 2002 <sup>355</sup>	6/140	1/138	5.914	0.721	48.486	10.52	0.036	-0.001	0.072	6.26
Castro-Diaz, 2007 <sup>254</sup>	4/136	0/120	7.949	0.432	146.134	5.5	0.029	-0.003	0.061	7.91
Lin, 2008 <sup>339</sup>	2/60	0/61	5.082	0.249	103.691	5.12	0.033	-0.021	0.088	2.94
Dmochowski, 2003 <sup>279</sup>	22/344	0/339	44.348	2.701	728.141	5.95	0.064	0.038	0.09	11.02
Bent, 2008 <sup>234</sup>	7/300	0/288	14.402	0.826	251.018	5.7	0.023	0.005	0.042	19.61

**Appendix Table F43. Adverse effects that result in discontinuation of the treatment after duloxetine vs. placebo, random effects models (continued)**

Reference	Active events/ randomized	Control events/ randomized	Relative risk	Lower (95% CI)	Upper (95% CI)	Weight	Absolute risk difference	Lower (95% CI)	Upper (95% CI)	Weight
Pooled estimate			11.267	5.693	22.295	100	0.04	0.031	0.05	100
I squared			0.00%				16.40%			
p value for heterogeneity			0.958				0.297			
<b>Somnolence</b>										
Norton, 2002 <sup>355</sup>	2/140	0/138	4.667	0.227	95.996	12.04	0.019	-0.013	0.052	2.74
Bent, 2008 <sup>234</sup>	3/300	0/288	9.969	1.279	77.721	26.09	0.009	0.003	0.016	63.07
Lin, 2008 <sup>339</sup>	2/60	0/61	4.929	0.239	101.744	12.01	0.014	-0.01	0.038	5.02
Dmochowski, 2003	7/344	1/339	5.082	0.249	103.691	12.1	0.033	-0.021	0.088	0.97
Hurley, 2006 <sup>312</sup>	10/958	1/955	6.898	0.853	55.767	25.19	0.017	0.001	0.033	11.24
Ghoniem, 2005 <sup>293</sup>	2/104	0/97	6.721	0.349	129.543	12.57	0.01	-0.003	0.023	16.96
Pooled estimate			6.684	2.341	19.081	100	0.011	0.006	0.017	100
I squared			0.00%				0.00%			
p value for heterogeneity			0.998				0.874			
<b>Any adverse event</b>										
Millard, 2004 <sup>350</sup>	39/227	4/231	9.922	3.604	27.312	9.98	0.154	0.103	0.206	11.06
Cardozo, 2004 <sup>251</sup>	18/55	3/54	5.891	1.841	18.851	9.37	0.272	0.133	0.41	7.66
Castro-Diaz, 2007 <sup>254</sup>	22/136	7/120	5	0.241	103.616	3.8	0.008	-0.006	0.022	11.87
Bent, 2008 <sup>234</sup>	47/300	9/288	2.957	1.299	6.731	10.72	0.099	0.03	0.169	10.45
Norton, 2002 <sup>355</sup>	21/140	7/138	2.773	1.228	6.261	10.75	0.103	0.029	0.178	10.26
Lin, 2008 <sup>339</sup>	16/60	4/61	4.067	1.443	11.46	9.88	0.201	0.073	0.329	8.07
Schagen van Leeuwen, 2008 <sup>378</sup>	15/131	7/134	2.192	0.924	5.202	10.56	0.062	-0.004	0.129	10.57
Dmochowski, 2003 <sup>279</sup>	83/344	14/339	5.842	3.384	10.086	11.66	0.2	0.15	0.25	11.12
Duckett, 2007 <sup>285</sup>	21/67	74/148	0.627	0.425	0.925	12.08	-0.187	-0.324	-0.049	7.7
van Kerrebroeck, 2004 <sup>393</sup>	2/247	0/247	5.013	2.503	10.041	11.19	0.125	0.08	0.171	11.24
Pooled estimate			3.434	1.691	6.974	100	0.105	0.041	0.169	100
I squared			87.40%				92.80%			
p value for heterogeneity			0.00%				0.00%			
<b>Diarrhea</b>										
Bent, 2008 <sup>234</sup>	3/300	1/288	1.994	0.181	21.951	46.97	0.001	-0.003	0.005	93.23
Hurley, 2006 <sup>312</sup>	2/958	1/955	2.88	0.301	27.527	53.03	0.007	-0.007	0.02	6.77
Pooled estimate			2.423	0.468	12.541	100	0.001	-0.002	0.005	100
I squared			0.00%				0.00%			

**Appendix Table F43. Adverse effects that result in discontinuation of the treatment after duloxetine vs. placebo, random effects models (continued)**

Reference	Active events/ randomized	Control events/ randomized	Relative risk	Lower (95% CI)	Upper (95% CI)	Weight	Absolute risk difference	Lower (95% CI)	Upper (95% CI)	Weight
p value for heterogeneity			0.827				0.43			
<b>Headache</b>										
Norton, 2002 <sup>355</sup>	3/136	1/120	4.929	0.239	101.744	25.72	0.014	-0.01	0.038	22.85
Castro-Diaz, 2007 <sup>254</sup>	4/300	0/288	2.647	0.279	25.11	46.58	0.014	-0.016	0.043	15
Bent, 2008 <sup>234</sup>	3/136	1/120	8.641	0.467	159.784	27.7	0.013	-0.001	0.028	62.15
Pooled estimate			4.311	0.928	20.016	100	0.014	0.002	0.025	100
I squared			0.00%				0.00%			
p value for heterogeneity			0.816				0.998			